EydisBio, Inc.

EydisBio, Inc is a Durham, North Carolina-based biopharmaceutical company specializing in the development of highly selective protein kinase inhibitors.

We are dedicated to addressing significant unmet medical needs in autoimmune and inflammatory diseases, such as rheumatoid arthritis, chronic pain, and systemic sclerosis. Our core focus is on TAK1 inhibitors, a novel class of drugs designed to provide safer and more effective treatments by targeting inflammation at its source.

EydisBio’s proprietary inhibitors represent a significant advancement in therapeutic approaches, offering locally-acting, orally bioavailable solutions with the potential to overcome immune-induced therapy resistance. We are currently conducting in vivo efficacy and pilot safety studies, exploring applications beyond RA, including viral-induced ARDS and chronic pain management.

Founded by Dr. Timothy Haystead, a seasoned biotechnology leader with extensive experience in small molecule discovery, EydisBio is committed to translating innovative research into tangible benefits for patients.